Open-Label Study of AG10 in Patients With Cardiomyopathy

Status Active, not recruiting

Clinical Trial Summary

This prospective, multicenter open-label study will evaluate the long-term safety, tolerability, PK and PD of AG10 administered on a background of stable heart failure therapy.

Clinical Trial Description

An Open-Label Extension and Safety Monitoring Study of Patients with Symptomatic Transthyretin Cardiomyopathy Who Have Completed the Phase II Study AG10-201 The primary objective of this study is to evaluate the long-term safety and tolerability of AG10 administered to adult patients with symptomatic transthyretin amyloid cardiomyopathy (ATTR-CM) in patients who have completed the study AG10-201. This study will be an Open-Label Extension and Safety Monitoring Study of up to 55 male and/or female patients with symptomatic ATTR-CM aged 18 through 90 years, who have completed the Phase II Study AG10-201. Enrollment into the study will be followed by visits at Day 14, Day 45, 3 Months and every 3 months thereafter until Month 54. After the Month 54 Visit, study visits will be every 6 months. There will be one follow-up visit approximately 30 days after last dose. If all doses are well tolerated, the duration of each patient's participation in the study will continue based on periodic recommendations of the AG10 Data Monitoring Committee (DMC) and/or registration of the product for the treatment of symptomatic ATTR-CM. The secondary objectives of this study are to characterize the pharmacokinetics (PK) of AG10 administered orally twice daily in patients with symptomatic ATTR-CM, and to describe the long-term pharmacodynamic (PD) properties of AG10 as assessed by established assays of transthyretin (TTR) stabilization, including Fluorescent Probe Exclusion (FPE) assay and Western blot, and to describe the PK-PD relationship of AG10 in adult patients with symptomatic ATTR-CM. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT03536767
Study type	Interventional
Source	Eidos Therapeutics, a BridgeBio company
Contact
Status	Active, not recruiting
Phase	Phase 2
Start date	August 8, 2018
Completion date	July 2027

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05699044` - Screening of ATTRwt in Patient With Advanced AV-Block Undergoing Pacemaker Implantation
Active, not recruiting	`NCT04738266` - Unmasking the Prevalence of AC in an Unselected Echocardiographic Population
Recruiting	`NCT05797857` - Exercise Training in Transthyretin Cardiac Amyloidosis	N/A
Completed	`NCT03860935` - Efficacy and Safety of AG10 in Subjects With Transthyretin Amyloid Cardiomyopathy	Phase 3
Recruiting	`NCT03397810` - Effect of Radiotherapy on ATTR Cardiac Amyloidosis : a Proof of Concept Study	N/A
Recruiting	`NCT05795400` - Administration of the SGLT-2 Inhibitor Dapagliflozin in the Patients With Amyloid Cardiomyopathy	N/A
Recruiting	`NCT06048601` - 18F-florbetaben PET-CT to Non-invasively Diagnose Cardiac AL Amyloidosis	N/A
Recruiting	`NCT06328075` - Artificial Intelligence to Assist the Echocardiographic Identification of Transthyretin Cardiac Amyloidosis
Recruiting	`NCT05103943` - Amyloidosis TTR Flow Reserve Evaluation	N/A
Recruiting	`NCT04776824` - Swiss Cardiac Amyloidosis REgistry (Swiss-CARE)
Recruiting	`NCT06261216` - Association Between Lifetime Physical Activity and Exercise and the Development of Wild-type Transthyretin Amyloid Cardiomyopathy
Active, not recruiting	`NCT03431896` - Monitoring of Early Disease Progression in Hereditary Transthyretin Amyloidosis
Active, not recruiting	`NCT05452850` - Longitudinal Changes in Left and Right Ventricular Global Strain After Chemotherapy in Cardiac Light Chain Amyloidosis
Active, not recruiting	`NCT05448716` - Left Atrial Strain and Supraventricular Arrhythmia Burden in Cardiac Light Chain Amyloidosis Following Chemotherapy